Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 80
- 主要终点
- Serum level of Developmental Endothelial Locus-1 (DEL-1). Time Frame: Baseline
研究概览
简要总结
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression.
Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction.
This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity.
This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients aged between 18 and 70 years.
- •Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.
- •Patients undergoing evaluation or follow-up for diabetic kidney disease.
- •Ability and willingness to provide informed consent.
排除标准
- •- Patients with known hepatic disease.
- •Patients with significant cardiovascular disease.
- •Patients with malignancy.
- •Patients who have undergone recent surgery.
- •Patients with known hematological disorders or hypercoagulable states.
- •Patients receiving medications that significantly affect platelet function.
研究组 & 干预措施
Control
Healthy individuals without diabetes or kidney disease.
干预措施: No intervention (Other)
Patients
Patients diagnosed with diabetic nephropathy.
干预措施: No intervention (Other)
结局指标
主要结局
Serum level of Developmental Endothelial Locus-1 (DEL-1). Time Frame: Baseline
时间窗: Baseline
Measurement of serum DEL-1 levels in patients with diabetic nephropathy compared with healthy controls.
次要结局
未报告次要终点
研究者
Amani Muhammed Abdelfattah Seleem
Assistant Lecturer of Medical Physiology
Aswan University